Illumina, Inc., (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that effective today it has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology.
"The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy," said Steven Barnard, chief technology officer of Illumina. "Single-cell research opens doors to new areas of discovery, and Fluent's innovative, accessible, and flexible single-cell method will accelerate our ability to deliver full multiomics solutions for our customers."
Fluent's single-cell analysis technology eliminates the need for complex, expensive instrumentation and microfluidic consumables. This novel approach removes many of the barriers and limitations of current methods, making single-cell analysis accessible for a broader set of customers, and catalyzing new experiments enabled by the ability to perform that assay at the point of sample collection. Fluent's latest release, PIPseq™ V, delivers exceptional performance, with the ability to detect cell types often missed with current methods, and the highest scalability, capable of processing a range from 100 cells up to 1 million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.